EA201990778A1 - Анти-il-33 антитела и их применение - Google Patents

Анти-il-33 антитела и их применение

Info

Publication number
EA201990778A1
EA201990778A1 EA201990778A EA201990778A EA201990778A1 EA 201990778 A1 EA201990778 A1 EA 201990778A1 EA 201990778 A EA201990778 A EA 201990778A EA 201990778 A EA201990778 A EA 201990778A EA 201990778 A1 EA201990778 A1 EA 201990778A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
application
treatment
bind
agents
Prior art date
Application number
EA201990778A
Other languages
English (en)
Inventor
Роберт Ян Беншоп
Джулиан Дэвис
Анжела Жанин Окрэгли
Четанкумар Натварлал Пател
Стефани Мари Трухлар
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201990778A1 publication Critical patent/EA201990778A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Предложены антитела, которые связывают и нейтрализуют IL-33 человека, а также способы их применения, при этом указанные антитела пригодны в качестве агентов для лечения патологических состояний, ассоциированных с аллергическим заболеванием, в том числе для лечения атопического дерматита.
EA201990778A 2016-10-28 2017-10-24 Анти-il-33 антитела и их применение EA201990778A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662414258P 2016-10-28 2016-10-28
PCT/US2017/058020 WO2018081075A1 (en) 2016-10-28 2017-10-24 Anti-il-33 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA201990778A1 true EA201990778A1 (ru) 2019-09-30

Family

ID=60263117

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990778A EA201990778A1 (ru) 2016-10-28 2017-10-24 Анти-il-33 антитела и их применение

Country Status (36)

Country Link
US (2) US10501536B2 (ru)
EP (1) EP3532499B1 (ru)
JP (1) JP6830533B2 (ru)
KR (1) KR102266144B1 (ru)
CN (1) CN109863173B (ru)
AR (1) AR109948A1 (ru)
AU (1) AU2017351183B2 (ru)
BR (1) BR112019005139A2 (ru)
CA (1) CA3039232C (ru)
CL (1) CL2019001043A1 (ru)
CO (1) CO2019003047A2 (ru)
CR (1) CR20190179A (ru)
CY (1) CY1124360T1 (ru)
DK (1) DK3532499T3 (ru)
EA (1) EA201990778A1 (ru)
EC (1) ECSP19029758A (ru)
ES (1) ES2878037T3 (ru)
HR (1) HRP20211221T1 (ru)
HU (1) HUE055621T2 (ru)
IL (1) IL265689B2 (ru)
JO (1) JOP20190093A1 (ru)
LT (1) LT3532499T (ru)
MA (1) MA46619B1 (ru)
MD (1) MD3532499T2 (ru)
MX (1) MX2019004863A (ru)
PE (1) PE20191045A1 (ru)
PH (1) PH12019500929A1 (ru)
PL (1) PL3532499T3 (ru)
PT (1) PT3532499T (ru)
RS (1) RS62120B1 (ru)
SI (1) SI3532499T1 (ru)
TN (1) TN2019000086A1 (ru)
TW (2) TWI676680B (ru)
UA (1) UA121293C2 (ru)
WO (1) WO2018081075A1 (ru)
ZA (1) ZA201901935B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
KR20220054689A (ko) 2019-10-15 2022-05-03 일라이 릴리 앤드 캄파니 재조합적으로 조작된, 리파제/에스테라제-결핍 포유동물 세포주
AU2020379171A1 (en) 2019-11-04 2022-06-09 Medimmune Limited Methods of using IL-33 antagonists
AU2020380588A1 (en) 2019-11-04 2022-06-09 Medimmune Limited Anti IL-33 therapeutic agent FPR treating renal disorders
CN115605507A (zh) 2020-03-13 2023-01-13 基因泰克公司（Us） 抗白介素-33抗体及其用途
JP2023516497A (ja) 2020-03-13 2023-04-19 メドイミューン・リミテッド Ｉｌ３３にリスクアレルを有する対象を治療するための治療方法
JP2023521061A (ja) 2020-04-06 2023-05-23 メドイミューン・リミテッド Ｉｌ－３３軸結合アンタゴニストによる急性呼吸窮迫症候群の治療
AU2021270839A1 (en) 2020-05-11 2023-02-02 Medimmune Limited Formulations of anti-IL-33 antibodies
CN111620948B (zh) * 2020-06-10 2022-04-08 南京赛新生物科技有限公司 针对il-33的抗体
CN113603775B (zh) * 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2024038185A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Method of selecting patients for treatment with an il-33 axis antagonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
CA2685124A1 (en) 2007-04-26 2008-11-06 Provost, Fellows And Scholars Of The College Of The Holy And Undivided T Rinity Of Queen Elizabeth Near Dublin Products for altering il-33 activity and methods therefor
JP2010527936A (ja) 2007-05-18 2010-08-19 メディミューン，エルエルシー 炎症性疾患におけるｉｌ−３３
US20120263709A1 (en) 2009-09-10 2012-10-18 Schering Corporation Use of il-33 antagonists to treat fibrotic diseases
WO2012113813A1 (en) * 2011-02-23 2012-08-30 F. Hoffmann-La Roche Ag Antibodies against human il33r and uses thereof
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EP3088517B1 (en) * 2013-12-26 2023-11-01 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 neutralizing monoclonal antibody
MX2016009047A (es) * 2014-01-10 2017-04-13 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (il-33).
CA2946511C (en) * 2014-04-21 2023-08-22 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
PE20170910A1 (es) 2014-11-10 2017-07-12 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos
CA2982400C (en) 2015-03-31 2023-10-24 Medimmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
JP2019508382A (ja) 2016-01-14 2019-03-28 アナプティスバイオ インコーポレイティッド Ｉｌ−３３阻害剤を使用したアレルギー反応の阻害
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها

Also Published As

Publication number Publication date
SI3532499T1 (sl) 2021-08-31
US20200048340A1 (en) 2020-02-13
IL265689B1 (en) 2023-10-01
AU2017351183B2 (en) 2020-04-09
US20180118821A1 (en) 2018-05-03
BR112019005139A2 (pt) 2019-06-04
LT3532499T (lt) 2021-08-10
TW201829459A (zh) 2018-08-16
PH12019500929A1 (en) 2019-12-02
AR109948A1 (es) 2019-02-06
MA46619B1 (fr) 2021-09-30
CA3039232C (en) 2021-05-25
AU2017351183A1 (en) 2019-04-11
TWI676680B (zh) 2019-11-11
CA3039232A1 (en) 2018-05-03
RS62120B1 (sr) 2021-08-31
KR102266144B1 (ko) 2021-06-18
IL265689B2 (en) 2024-02-01
CO2019003047A2 (es) 2019-04-12
IL265689A (en) 2019-05-30
WO2018081075A1 (en) 2018-05-03
CR20190179A (es) 2019-08-26
EP3532499A1 (en) 2019-09-04
PE20191045A1 (es) 2019-08-06
MD3532499T2 (ro) 2021-09-30
EP3532499B1 (en) 2021-05-05
PT3532499T (pt) 2021-07-05
UA121293C2 (uk) 2020-04-27
CL2019001043A1 (es) 2019-08-30
HRP20211221T1 (hr) 2021-10-29
US10913793B2 (en) 2021-02-09
CN109863173B (zh) 2022-06-03
HUE055621T2 (hu) 2021-12-28
CY1124360T1 (el) 2022-07-22
CN109863173A (zh) 2019-06-07
TN2019000086A1 (en) 2020-07-15
ECSP19029758A (es) 2019-05-31
PL3532499T3 (pl) 2021-11-08
DK3532499T3 (da) 2021-06-28
JP2019534282A (ja) 2019-11-28
ES2878037T3 (es) 2021-11-18
ZA201901935B (en) 2020-11-25
JOP20190093A1 (ar) 2019-04-25
JP6830533B2 (ja) 2021-02-17
KR20190054160A (ko) 2019-05-21
TW201920675A (zh) 2019-06-01
MX2019004863A (es) 2019-08-12
TWI647238B (zh) 2019-01-11
US10501536B2 (en) 2019-12-10

Similar Documents

Publication Publication Date Title
EA201990778A1 (ru) Анти-il-33 антитела и их применение
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201790377A1 (ru) Антитела к глюкагону и их применения
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
EA201790413A1 (ru) Антитела против tigit
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201992546A1 (ru) Средства на основе антител к cd33
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201591716A1 (ru) Антитела анти-il-33 и их применение
EA201590402A1 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА ПРОТИВ GFRα3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201492282A1 (ru) Антагонистические антигенсвязывающие белки к двум рецепторам и их применение
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EA201691541A1 (ru) Новые анти-baff антитела
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201501061A1 (ru) Антитела к igf-1r с элиминированной способностью связываться с fcrn и их применение для лечения сосудистых глазных заболеваний
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
EP3500293A4 (en) METHODS OF TREATING CROHN'S DISEASE WITH AN ANTI-NKG2D ANTIBODY
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
EA201891594A1 (ru) Антитела к il-17c
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA201990493A1 (ru) Антитела к гм-ксф и их применения